NilvadipineCa2+ channel blocker (L-type); also Syk kinase inhibitor CAS# 75530-68-6 |
2D Structure
- Mibefradil
Catalog No.:BCC1748
CAS No.:116644-53-2
- Mibefradil dihydrochloride
Catalog No.:BCC1749
CAS No.:116666-63-8
- Cilnidipine
Catalog No.:BCC1083
CAS No.:132203-70-4
- NNC 55-0396
Catalog No.:BCC1803
CAS No.:357400-13-6
- NP118809
Catalog No.:BCC1807
CAS No.:41332-24-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 75530-68-6 | SDF | Download SDF |
PubChem ID | 4494 | Appearance | Powder |
Formula | C19H19N3O6 | M.Wt | 385.37 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 50 mg/mL (129.75 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 3-O-methyl 5-O-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | ||
SMILES | CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C | ||
Standard InChIKey | FAIIFDPAEUKBEP-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Syk inhibitor. Blocks Aβ production, APPβ secretion and reduces BACE-1 expression in CHO cells over-expressing Aβ in vitro. Enhances clearance of Aβ across the blood brain barrier in vivo. Reduces brain Aβ levels in a mouse tauopathy model. Also L-type calcium channel blocker and antihypertensive. |
Nilvadipine Dilution Calculator
Nilvadipine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5949 mL | 12.9745 mL | 25.9491 mL | 51.8982 mL | 64.8727 mL |
5 mM | 0.519 mL | 2.5949 mL | 5.1898 mL | 10.3796 mL | 12.9745 mL |
10 mM | 0.2595 mL | 1.2975 mL | 2.5949 mL | 5.1898 mL | 6.4873 mL |
50 mM | 0.0519 mL | 0.2595 mL | 0.519 mL | 1.038 mL | 1.2975 mL |
100 mM | 0.0259 mL | 0.1297 mL | 0.2595 mL | 0.519 mL | 0.6487 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Nilvadipine(FR34235) is a calcium channel blocker for treatment of hypertension.
- Cedrin
Catalog No.:BCN4748
CAS No.:75513-81-4
- Flupirtine maleate
Catalog No.:BCC4456
CAS No.:75507-68-5
- BI6727 (Volasertib)
Catalog No.:BCC3886
CAS No.:755038-65-4
- BI 2536
Catalog No.:BCC2081
CAS No.:755038-02-9
- Regorafenib
Catalog No.:BCC3646
CAS No.:755037-03-7
- N-Methylnuciferine
Catalog No.:BCN3971
CAS No.:754919-24-9
- CGP 37157
Catalog No.:BCC6943
CAS No.:75450-34-9
- Moxonidine
Catalog No.:BCC2142
CAS No.:75438-57-2
- EHT 1864
Catalog No.:BCC6075
CAS No.:754240-09-0
- Boc-Asp(OBzl)-OH
Catalog No.:BCC2608
CAS No.:7536-58-5
- Boc-Asn-OH
Catalog No.:BCC3071
CAS No.:7536-55-2
- Indacaterol Maleate
Catalog No.:BCC4358
CAS No.:753498-25-8
- Moxonidine hydrochloride
Catalog No.:BCC5163
CAS No.:75536-04-8
- Dencichin
Catalog No.:BCN2555
CAS No.:7554-90-7
- Ingenol 3-Angelate
Catalog No.:BCN2961
CAS No.:75567-37-2
- 20-Deoxyingenol 3-angelate
Catalog No.:BCN6642
CAS No.:75567-38-3
- Sodium phosphate dibasic
Catalog No.:BCC7585
CAS No.:7558-79-4
- Sodium phosphate monobasic
Catalog No.:BCC8033
CAS No.:7558-80-7
- alpha-Tocopherolquinone
Catalog No.:BCN4305
CAS No.:7559-04-8
- Kaerophyllin
Catalog No.:BCN4304
CAS No.:75590-33-9
- Methyl 3,4,5-trimethoxycinnamate
Catalog No.:BCN4589
CAS No.:7560-49-8
- Fludarabine Phosphate (Fludara)
Catalog No.:BCC3681
CAS No.:75607-67-9
- (S)-(+)-α-Methylhistamine dihydrobromide
Catalog No.:BCC6700
CAS No.:75614-93-6
- (-)-Usnic acid
Catalog No.:BCN4306
CAS No.:7562-61-0
Histological protection by nilvadipine against neurotoxicity induced by NOC12, a nitric oxide donor, in the rat retina.[Pubmed:24492726]
Biol Pharm Bull. 2014;37(2):306-10.
In the present study, we histologically examined the effects of Nilvadipine on neuronal injury induced by intravitreal (i.v.) N-methyl-D-aspartate (NMDA) (200 nmol/eye) and intravitreal NOC12 (400 nmol/eye), a nitric oxide donor, in the rat retina. Morphometric evaluation at 7 d after injection of NMDA or NOC12 showed that treatment with Nilvadipine (1 mg/kg, i.v.) 15 min prior to injection of NMDA or NOC12 dramatically reduced the retinal damage. These results suggest that Nilvadipine protects neurons against excitotoxic injury in the rat retina in vivo at least in part via an antioxidative effect.
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow.[Pubmed:27436668]
BMJ Open. 2016 Jul 19;6(7):e011584.
INTRODUCTION: In conjunction with the NILVAD trial, a European Multicentre Double-Blind Placebo Controlled trial of Nilvadipine in Mild-to-Moderate Alzheimer's disease (AD), there are four NILVAD substudies in which eligible NILVAD patients are also invited to participate. The main NILVAD protocol was previously published in BMJ Open (2014). The objectives of the NILVAD substudies are to determine whether frailty, cerebrospinal fluid (CSF), blood biomarker profile and Apolipoprotein E (APOE) status predict response to Nilvadipine, and to investigate the effect of Nilvadipine on cerebral blood flow and blood biomarkers. METHODS AND ANALYSIS: All participants who fulfil criteria for the main NILVAD study are eligible for participation in the NILVAD substudies. Participation is subject to informed consent and whether the substudy is available at a particular NILVAD study site. Each substudy entails extra measurements during the course of the main NILVAD study. For example, in the blood and genetic biomarkers substudy, extra blood (30 mL) will be collected at week 0, week 13, week 52 and week 78, while in the cerebral blood flow substudy, participants will receive an MRI and transcranial Doppler measurements at week 0, week 26 and week 78. In the CSF substudy, 10 mL CSF is collected at week 0 and week 78. ETHICS AND DISSEMINATION: All NILVAD substudies and all subsequent amendments have received ethical approval within each participating country, according to national regulations. Each participant provides written consent to participate. All participants remain anonymised throughout and the results of each substudy will be published in an international peer reviewed journal. TRIAL REGISTRATION NUMBER: EUDRACT 2012-002764-27; Pre-results.
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.[Pubmed:25300460]
BMJ Open. 2014 Oct 9;4(10):e006364.
INTRODUCTION: This study is a European multicentre, randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of Nilvadipine as a disease course modifying treatment for mild-to-moderate Alzheimer's disease (AD) in a phase III study that will run for a period of 82 weeks with a treatment period of 78 weeks. METHODS AND ANALYSIS: Adult patients, males and females over 50 years with mild-to-moderate AD as defined by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) criteria, will be included in the study. It aims to recruit a total of 500 patients with AD; 250 in the Nilvadipine group and 250 in the placebo group. Participants will be randomised to receive Nilvadipine, an 8 mg overencapsulated, sustained release capsule, or a matching overencapsulated placebo (sugar pill) for a period of 78 weeks of treatment. The primary efficacy outcome measure in this study is the change in cognitive function as assessed by the Alzheimer's disease Assessment Scale (ADAS-Cog 12) from baseline to the end of treatment duration (78 weeks). There are two key secondary outcome measures, the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) and the Disability Assessment for Dementia (DAD). If a statistically significant effect is seen in the primary outcome, CDR-sb will be considered to be a coprimary end point and only the DAD will contribute to the secondary outcome analysis. ETHICS AND DISSEMINATION: The study and all subsequent amendments have received ethical approval within each participating country according to national regulations. Each participant will provide written consent to participate in the study. All participants will remain anonymised throughout and the results of the study will be published in an international peer-reviewed journal. TRIAL REGISTRATION NUMBER: EUDRACT Reference Number: 2012-002764-27.
Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity.[Pubmed:2552119]
J Med Chem. 1989 Oct;32(10):2399-406.
The novel calcium antagonists 3-N-substituted-3,4-dihydropyrimidines 1 and 9 and 3-N-substituted-dihydro-pyrimidin-2(1H)-ones 8 were regioselectively synthesized in good yields. Compounds 1 [especially 1s [R1 = (CH2)2N(benzyl)(2-naphthylmethyl), R2 = i-Pr, X = 0-NO2] and 1t [R1 = (CH2)2N(benzyl)(3,4-dichlorobenzyl), R2 = i-Pr, X = 0-NO2]] exhibited not only more potent and longer lasting vasodilative action but also a hypotensive activity with slow onset as compared with dihydropyridines. Moreover, some dihydropyrimidines [1q [R1 = (CH2)2N(benzyl)(3-phenylpropyl), R2 = CH2(cyclopropyl), X = 0-NO2], 1s, and 1t] were weaker in blocking atrioventricular conduction in anesthetized open-chest dogs and less toxic than the dihydropyridines.